Clinical Trial Update: Metformin With Standard Taxotere and Prednisone in the Treatment of Castration Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating metformin with standard Taxotere (docetaxel) and prednisone in castration-resistant prostate cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• PREDNISONE (Prednisone)
• Taxotere (docetaxel)
• metformin (metformin)

Snippet

Sponsor: New Mexico Cancer Research Alliance | Conditions: Prostate Cancer | Phase 2 | Status: WITHDRAWN